Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-13
2008-05-13
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S330000, C544S331000, C544S332000
Reexamination Certificate
active
10946055
ABSTRACT:
Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosiswherein X is N or CR5;and pharmaceutically acceptable salts thereof,wherein R1to R7are as defined herein.A method for treating the above diseases employing the above compounds is also provided.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 4027009 (1977-05-01), Grier et al.
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4168267 (1979-09-01), Petrillo, Jr.
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4405552 (1983-09-01), Miesel
patent: 4432971 (1984-02-01), Karanewsky et al.
patent: 4452790 (1984-06-01), Karanewsky et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4639436 (1987-01-01), Junge et al.
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 4929437 (1990-05-01), Tobert
patent: 4933165 (1990-06-01), Brown
patent: 5100889 (1992-03-01), Misra et al.
patent: 5223516 (1993-06-01), Delaney et al.
patent: 5225401 (1993-07-01), Seymour
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5316765 (1994-05-01), Folkers et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5362727 (1994-11-01), Robl
patent: 5366973 (1994-11-01), Flynn et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5504080 (1996-04-01), Karanewsky
patent: 5525723 (1996-06-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5646176 (1997-07-01), Golik et al.
patent: 5698527 (1997-12-01), Kim
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6218408 (2001-04-01), Marzabadi et al.
patent: RE37314 (2001-08-01), Hirai et al.
patent: 6395767 (2002-05-01), Robl et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6469024 (2002-10-01), Li et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 6525203 (2003-02-01), Tino
patent: 6548529 (2003-04-01), Robl et al.
patent: 6573287 (2003-06-01), Sulsky et al.
patent: 6750246 (2004-06-01), Kadow et al.
patent: 6800605 (2004-10-01), Friends et al.
patent: 40 23 308 (1992-01-01), None
patent: 196 22 222 (1997-12-01), None
patent: 0 367 895 (1990-05-01), None
patent: 0416383 (1991-03-01), None
patent: 0 465 970 (1992-01-01), None
patent: 0 534 396 (1996-10-01), None
patent: 0 595 610 (1997-05-01), None
patent: 0 534 363 (1997-07-01), None
patent: 0 481 522 (1997-12-01), None
patent: 0 599 444 (1998-01-01), None
patent: 0 675 714 (1999-01-01), None
patent: 0 970 694 (2000-01-01), None
patent: 0 992 496 (2000-04-01), None
patent: 0 521 471 (2000-10-01), None
patent: 0 818 448 (2003-11-01), None
patent: 0 629 627 (2004-05-01), None
patent: 1 022 272 (2004-05-01), None
patent: 2 304 106 (1997-03-01), None
patent: 6-256318 (1994-09-01), None
patent: WO 94/14787 (1994-07-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/44609 (1999-09-01), None
patent: WO 99/45913 (1999-09-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/58518 (1999-11-01), None
patent: WO 99/58521 (1999-11-01), None
patent: WO 99/58522 (1999-11-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/61435 (1999-12-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/03746 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 00/53605 (2000-09-01), None
patent: WO 00/77010 (2000-12-01), None
patent: WO 01/13917 (2001-03-01), None
patent: WO 01/14376 (2001-03-01), None
patent: WO 02/098854 (2002-12-01), None
patent: WO 03/011824 (2003-02-01), None
patent: WO 03/072197 (2003-09-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Khan et al., Diabetes Care 25(4), 708-711, 2002.
Iida et al., FEBS Letters 520, 177-181, 2002.
Rutishauser Swiss Medical Weekly, 126, 41-49, 2006.
U.S. Appl. No. 10/989,138, filed Nov. 15, 2004, O'Connor et al.
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Beck, G. et al., “Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1. Lactones of Pyridine- and Pyrimidine-Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids”, J. Med. Chem. vol. 33, No. 1, pp. 52-60 (1990).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, J. Am. Chem. Soc., vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, No. 1, pp. 11-20 (1999).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol.16, No. 1, pp. 16-30 (1998).
Hara, S., “lleal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24, No. 4, pp. 425-430 (1999).
Hughes, T.E. et al., “NVP-DPP728: (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]acetyl]-2-cyano-(S)-pyr
Ahmad Saleem
Ngu Khehyong
Robl Jeffrey A.
Balasubram Venkataraman
Bristol--Myers Squibb Company
Rodney Burton
LandOfFree
HMG-CoA reductase inhibitors and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HMG-CoA reductase inhibitors and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HMG-CoA reductase inhibitors and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921216